<DOC>
	<DOCNO>NCT01936688</DOCNO>
	<brief_summary>This study conduct evaluate efficacy safety/tolerability SCH 900222/MK-3222 population participant moderate-to-severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety/Tolerability Subcutaneous MK-3222 Participants With Moderate-to-Severe Chronic Plaque Psoriasis ( MK-3222-012 )</brief_title>
	<detailed_description>The base study consist screen phase 4 week follow treatment period 28 week , 20-week safety follow-up period drug . The base study divide 2 sequential part . In Part 1 base study ( Week 0 Week 12 ) , participant randomize one 4 study arm ( Arm A : MK-3222 200 mg Week 0 Week 4 + match placebo etanercept twice weekly ; Arm B : MK-3222 100 mg Week 0 Week 4 + match placebo etanercept twice weekly ; Arm C : Matching placebo MK-3222 Week 0 Week 4 + match placebo etanercept twice weekly ; Arm D : Matching placebo MK-3222 Week 0 Week 4 + etanercept 50 mg twice weekly ) . In Part 2 base study ( Week 12 Week 28 ) , participant Arm A , Arm B , Arm D receive match placebo MK-3222 maintain blind Week 12 . Participants Arm A Arm B continue receive either MK-3222 200 mg ( Arm A ) MK-3222 100 mg ( Arm B ) Week 16 Week 28 also receive match placebo etanercept weekly study Week 28 . At study Week 12 , Arm C participant re-randomized receive first dose MK-3222 200 mg MK-3222 100 mg , receive additional dos study medication accord re-randomized treatment assignment Week 16 Week 28 . Participants Arm C also receive match placebo etanercept weekly treatment Week 28 . Participants Arm D continue weekly dos etanercept study Week 28 combination match placebo MK-3222 . For participant , completion Week 28 mark completion Part 2 overall base study . Participants originally assign Arm D participant discontinue treatment prior complete Part 2 eligible enroll extension . Participants ineligible opt enter extension study encourage complete 20-week follow-up period . Eligible participant choose enroll extension study additional treatment period 192 week follow additional 20 week follow-up period . Each participant receive MK-3222 200 mg MK-3222 100 mg every 12 week study Week 220 accord treatment assignment conclusion Part 2 base study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis moderatetosevere plaque psoriasis least 6 month prior enrollment ; Candidate phototherapy systemic therapy ; Premenopausal female participant must agree abstain heterosexual activity use medically approve method contraception use appropriate effective contraception per local regulation guideline For extension study : must complete Part 2 base study For extension study : must achieve least PASI50 response end Part 2 base study Nonplaque form psoriasis Presence history severe psoriatic arthritis wellcontrolled current treatment regimen Women childbearing potential pregnant , intend become pregnant , lactate Participant expect require topical therapy , phototherapy , systemic therapy Presence infection history recurrent infection require treatment systemic antibiotic Previous use MK3222/SCH 900222 , interleukin23 ( IL23 ) /T helper cell 17 ( Th17 ) pathway inhibitor include P40 , P19 , IL17 antagonists , etanercept Latex allergy sensitivity Active untreated latent tuberculosis ( TB ) For extension study : woman childbearing potential pregnant , intend become pregnant within 6 month complete trial , breast feeding For extension study : active uncontrolled significant organ dysfunction clinically significant laboratory abnormality For extension study : expect require topical treatment , phototherapy , systemic treatment extension study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>